US veterans see PTSD remission in psilocybin pilot study

A small U.S. pilot trial involving 12 military veterans with treatment‑resistant post‑traumatic stress disorder reported that nine participants no longer met PTSD criteria one month after receiving two doses of synthetic psilocybin combined with intensive psychotherapy. The 11‑week protocol included eight hours of psychotherapy before dosing, two psilocybin sessions spaced two to three weeks apart, and additional integrative therapy afterward. The most common side effect was a mild headache. The study, led by Alan Davis of Ohio State University’s College of Social Work, is the first formal test of psilocybin in veterans and was designed to assess safety rather than efficacy. President Donald Trump’s April executive order to accelerate psychedelic‑treatment reviews and increase federal research funding underpins the growing interest in such therapies. Researchers hope to secure funding for a larger randomized trial.